Pepleomycin sulfate (NK 631) による頭頸部癌の治療と組織学的知見
Pepleomycin sulfate (NK 631) による頭頸部癌の治療と組織学的知見
复制标题
硫酸百霉素 (NK 631) 治疗头颈癌和组织学结果
DOI：
10.11553/antibiotics1968b.31.651
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
T. Yanagita
中科院分区：
文献类型：
--
作者：
Y. Matsumura;Y. Nomura;S. Eguchi;T. Yanagita
本文报道了一种新的抗肿瘤药物人霉素治疗头颈部肿瘤患者的临床表现和组织病理学表现。新药总剂量平均在100mg以内；然而，对化疗的反应总体上是相当有利的。人霉素在2例患者中显著有效，7例患者中有效，1例无效。显微镜下发现6种手术材料有癌细胞消退的迹象。研究表明，人霉素比博来霉素对鳞状细胞癌有更强的选择性作用。周围组织和皮肤对联合治疗的反应，包括人霉素，仍然与博来霉素相当。该药的副作用是轻微发烧和短暂性厌食。观察8个月，未见肺纤维化。
Clinical findings and histopathological appearances in the patients with cancer of the head and neck treated with a new anti-tumor agent, pepleomycin, are reported. The total dosage of the new drug was within 100 mg on the average; however, the responses to chemotherapy were considerably favorable in general. Pepleomycin was markedly effective in two patients, moderately effective in seven, and ineffective in one. Microscopic evidences of regression of cancer cells were demonstrated in six surgical materials. Pepleomycin was shown to have an even more selective action on squamous cell carcinoma than bleomycin. The reactions of the surrounding tissue and skin to combination therapy, including pepleomycin, remained comparable to those to bleomycin. Side effects of the drug were slight fever and transient anorexia. No fibrosis of the lung was seen during eight months of observation.